STEMdiff™ 血管类器官试剂盒

用于将人多能干细胞分化为血管类器官的培养基和补充试剂

只有 %1 左

率先评论此产品

¥18,722.00

产品号 #（选择产品）

产品号 #100-0651_C

用于将人多能干细胞分化为血管类器官的培养基和补充试剂

产品优势

生成具有生理相关性的三维血管类器官，非常适用于疾病建模和药物发现
提供标准化操作流程，配套优化试剂，可高效生成人多能干细胞（hPSC）衍生的类器官
支持96孔板形式的高通量扩展，适用于药物筛选或测试

产品组分包括

STEMdiff™ 血管类器官聚集基础培养基，60 mL
STEMdiff™ 血管类器官聚集补充剂，15 mL
STEMdiff™ 血管类器官诱导基础培养基，100 mL
STEMdiff™ 血管类器官诱导补充剂，1 mL
STEMdiff™ 血管类器官中胚层诱导补充剂，1 mL
STEMdiff™ 血管类器官血管诱导补充剂，1 mL
STEMdiff™ 血管类器官成熟培养基，100 mL（目录号 #100-0658）

立即询价

总览

使用 STEMdiff™ 血管类器官试剂盒，轻松且高效地生成具有生理相关性的血管类器官，用于组织修复与再生研究，或在体外建立血管疾病模型。

使用 STEMdiff™ 血管类器官试剂盒，可高效、可重复地从人多能干细胞 (hPSC) 中生成血管类器官，并可选择扩大规模以进行 96 孔板的高通量筛选。与自制类器官培养体系相比，该试剂盒使用便捷，生成的类器官具备更广泛的、具生理意义的血管网络结构，表现出稳定的内皮细胞-周细胞相互作用。使用该试剂盒生成的血管类器官含有 CD31+/CD34+/CD144+/KDR+ 内皮细胞和 PDGFR-β+/CD146+/SMA+/NG-2+ 周细胞。简单的实验方案还免去了血清筛选和繁琐的实验方案优化工作，让您可以投入更多时间进行更重要的事情——您的实验。

使用 STEMdiff™ 血管类器官试剂盒搭配mTeSR™ Plus或mTeSR™1培养基，可轻松从 hPSC 过渡到类器官。为方便起见， hPSC衍生的血管类器官成熟所需的STEMdiff™ 血管类器官成熟培养基可作为试剂盒的一部分购买，也可单独购买。如需将hPSC分化为内皮细胞，请使用我们的STEMdiff™ 内皮细胞分化试剂盒。

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

文献 (2)

Modeling Aberrant Angiogenesis in Arteriovenous Malformations Using Endothelial Cells and Organoids for Pharmacological Treatment E. J. Oh et al. Cells 2025 Jul

Abstract

Arteriovenous malformations (AVMs) are congenital vascular anomalies defined by abnormal direct connections between arteries and veins due to their complex structure or endovascular approaches. Pharmacological strategies targeting the underlying molecular mechanisms are thus gaining increasing attention in an effort to determine the mechanism involved in AVM regulation. In this study, we examined 30 human tissue samples, comprising 10 vascular samples, 10 human fibroblasts derived from AVM tissue, and 10 vascular samples derived from healthy individuals. The pharmacological agents thalidomide, U0126, and rapamycin were applied to the isolated endothelial cells (ECs). The pharmacological treatments reduced the proliferation of AVM ECs and downregulated miR-135b-5p, a biomarker associated with AVMs. The expression levels of angiogenesis-related genes, including VEGF , ANG2 , FSTL1 , and MARCKS , decreased; in comparison, CSPG4 , a gene related to capillary networks, was upregulated. Following analysis of these findings, skin samples from 10 AVM patients were reprogrammed into induced pluripotent stem cells (iPSCs) to generate AVM blood vessel organoids. Treatment of these AVM blood vessel organoids with thalidomide, U0126, and rapamycin resulted in a reduction in the expression of the EC markers CD31 and α-SMA. The establishment of AVM blood vessel organoids offers a physiologically relevant in vitro model for disease characterization and drug screening. The authors of future studies should aim to refine this model using advanced techniques, such as microfluidic systems, to more efficiently replicate AVMs’ pathology and support the development of personalized therapies.

View publication

Reassessment of marker genes in human induced pluripotent stem cells for enhanced quality control Nature Communications 2024 Oct

Abstract

Human induced pluripotent stem cells (iPSCs) have great potential in research, but pluripotency testing faces challenges due to non-standardized methods and ambiguous markers. Here, we use long-read nanopore transcriptome sequencing to discover 172 genes linked to cell states not covered by current guidelines. We validate 12 genes by qPCR as unique markers for specific cell fates: pluripotency (CNMD, NANOG, SPP1), endoderm (CER1, EOMES, GATA6), mesoderm (APLNR, HAND1, HOXB7), and ectoderm (HES5, PAMR1, PAX6). Using these genes, we develop a machine learning-based scoring system, “hiPSCore”, trained on 15 iPSC lines and validated on 10 more. hiPSCore accurately classifies pluripotent and differentiated cells and predicts their potential to become specialized 2D cells and 3D organoids. Our re-evaluation of cell fate marker genes identifies key targets for future studies on cell fate assessment. hiPSCore improves iPSC testing by reducing time, subjectivity, and resource use, thus enhancing iPSC quality for scientific and medical applications. Quality control, including pluripotency testing of human iPSCs lacks standardization. Here, authors identify and validate gene markers to develop the machine learning-based hiPSCore to streamline pluripotency testing and elevate iPSC quality.

View publication

View All Publications

STEMdiff™ 血管类器官试剂盒

产品号 #100-0651

产品号 #（选择产品）

产品号 #100-0651_C

产品优势

产品组分包括

总览

产品说明书及文档

应用领域

相关材料与文献

Request Pricing

更多信息

Scientists Helping Scientists™

STEMdiff™ 血管类器官试剂盒

产品号 #100-0651

产品号 #（选择产品）

产品号 #100-0651_C

产品优势

产品组分包括

总览

产品说明书及文档

应用领域

相关材料与文献

技术资料 (6)

文献 (2)

Abstract

Abstract

Request Pricing

更多信息

欢迎您关注STEMCELL Technologies的微信公众平台